Memory-like NK Cell Therapy + BHV-1100 for Multiple Myeloma

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Biohaven Pharmaceuticals, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?

This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 in the peri-transplant setting in MM patients with minimal residual disease (MRD+) in first or second remission.

Eligibility Criteria

This trial is for newly diagnosed Multiple Myeloma patients who are transplant eligible, have responded to initial chemotherapy, still have minimal residual disease, and meet specific health criteria like good heart and kidney function. They must not have had certain prior treatments or other active cancers.

Inclusion Criteria

My disease shows minimal residual disease before stem cell collection and transplant.

I have symptoms of multiple myeloma and am starting chemotherapy.

My lungs are functioning well enough for a transplant evaluation.

See 14 more

Exclusion Criteria

I have had a stem cell transplant before.

I have previously received cellular therapies, such as NK cell therapy.

I have been treated with monoclonal antibodies before.

See 10 more

Treatment Details

Interventions

CIML NK Cells (NK Cell Therapy)
KP1237 (Other)
Low Dose IL-2 (Cytokine)

Trial OverviewThe study tests a combination of CIML NK cells with KP1237 and low dose IL-2 in patients before they undergo an autologous stem cell transplant. It aims to establish safety and potential effectiveness in reducing remaining cancer cells.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: BHV-1100 Combination TreatmentExperimental Treatment1 Intervention